Publications
Publications 13326 - 13350 de 33557
| Titre | DOI |
|---|---|
|
Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy S. Scialom; G. Malamut; B. Meresse; N. Guegan; N. Brousse; V. Verkarre; C. Derrieux; E. Macintyre; P. Seksik; G. Savoye; G. Cadiot; L. Vuitton; L. Marthey; F. Carbonnel; N. Cerf-Bensussan; C. Cellier 2015 |
10.1371/journal.pone.0125024 |
|
Gastrointestinal parasites of two populations of Arctic foxes (Vulpes lagopus) from north-east Greenland P.Nynne Skam Andreassen; N.Martin Schmidt; C.Moliin Out Kapel; M.Ulrich Christensen; B. Sittler; O. Gilg; H.Larsen Enemark; M.Nafi Solai Al-Sabi 2017 |
10.1080/17518369.2017.1308667 |
|
Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome S.K. Togarsimalemath; A. SI-Mohammed; M. Puraswani; A. Gupta; A. Vabret; S. Liguori; P. Mariani-Kurkdjian; A. Bagga; M.A. Dragon-Durey 2018 |
10.1038/s41390-018-0009-9 |
|
Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) B. Landi; J.Y. Blay; S. Bonvalot; M. Brasseur; J.Michel Coindre; J.Francois Emile; V. Hautefeuille; C. Honore; E. Lartigau; G. Mantion; M. Pracht; A. Le Cesne; M. Ducreux; O. Bouche; TNCD; FFCD; F.Natl Ctr L. L; G.Cooperateu Multidisciplinaire; SFCD; SFRO; SFED; S.Natl Franc Gastroenterolog 2019 |
10.1016/j.dld.2019.07.006 |
|
Gastrointestinal: Strangulated transomental hernia A. Malakhia; N. Badet; E. Delabrousse 2017 |
10.1111/jgh.13651 |
|
Gastropods from upper Pliensbachian-Toarcian (Lower Jurassic) sediments of Causses Basin, southern France and their recovery after the early Toarcian anoxic event R. Gatto; S. Monari; P. Neige; J.D. Pinard; R. Weis 2015 |
10.1017/S0016756814000788 |
|
GATA2 gene analysis in several forms of hematological malignancies including familial aggregations W.Sabri Hamadou; R. Mani; S. Besbes; V. Bourdon; Y. Ben Youssef; F. Eisinger; V. Mari; P. Gesta; H. Dreyfus; V. Bonadona; C. Dugast; H. Zattara; L. Faivre; T. Noguchi; A. Khelif; H. Sobol; Z. Soua 2017 |
10.1007/s00277-017-3076-9 |
|
GATAD2B-Associated Neurodevelopmental Disorder (GAND), further delineation of the phenotype in a series of 10 patients G. Vera; A. Sorlin; G. Delplancq; F. Lecoquierre; F. Petit; T. Smol; A. Ziegler; D. Bonneau; S. Mercier; P. Edery; G. Lesca; N. Chatron; B. Duban-Bedu; C. Colson; B. Gerard; B. Durand; Y. Capri; T. Frebourg; A. Lebre; G. Nicolas; P. Saugier-Veber; A. Guerrot 2019 |
|
|
GATAD2B-Associated Neurodevelopmental Disorder (GAND), further delineation of the phenotype in a series of 10 patients G. Vera; A. Sorlin; G. Delplancq; F. Lecoquierre; F. Petit; T. Smol; A. Ziegler; D. Bonneau; S. Mercier; P. Edery; G. Lesca; N. Chatron; B. Duban-Bedu; C. Colson; B. Gerard; B. Durand; Y. Capri; T. Frebourg; A. Lebre; G. Nicolas; P. Saugier-Veber; A. Guerrot 2019 |
|
|
GAUGING SCALE EFFECTS AND BIOGEOGRAPHICAL SIGNALS IN SIMILARITY DISTANCE DECAY ANALYSES: AN EARLY JURASSIC AMMONITE CASE STUDY A. Zacai; A. Brayard; J.L. Dommergues; C. Meister; G. Escarguel; R. Laffont; B. Vrielynck; E. Fara 2016 |
10.1111/pala.12250 |
|
Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML) J. Park; D. Lechevalier; R. Ak; M. Ferguson; K.H. Law; Y.T.T. Lee; S. Rachuri 2017 |
10.1520/SSMS20160008 |
|
GCKR polymorphism influences liver fat content in patients with type 2 diabetes J.M. Petit; D. Masson; B. Guiu; F. Rollot; L. Duvillard; B. Bouillet; M.C. Brindisi; P. Buffier; P. Hillon; J.P. Cercueil; B. Verges 2016 |
10.1007/s00592-015-0766-4 |
|
GDC Buffer Layer Synthesized by Reactive Magnetron Sputtering: Effect of Total Pressure and Thickness on SOFC Performances L. Bouleau; N. Coton; P. Coquoz; R. Ihringer; A. Billard; P. Briois 2020 |
10.3390/cryst10090759 |
|
GDF15 and Cardiac Cells: Current Concepts and New Insights L. Rochette; G. Dogon; M. Zeller; Y. Cottin; C. Vergely 2021 |
10.3390/ijms22168889 |
|
GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism L. Rochette; M. Zeller; Y. Cottin; C. Vergely 2021 |
10.1016/j.tem.2021.08.011 |
|
GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gcmcitabine in patients with carcinoma of an unknown primary (CUP). G. Martineau; A. Laplanche; A.W. Van de Wouw; G. Daugaard; C. Balana; N. Penal; L. Chalgneau; D. Allouache; B. Chauffert; S. Culine; M. Gross-Goupil; Y. Marrouche; C. Moldovan; E. Vauleon; I. Borget; F. Wunder; C.A. Schnabel; K. Fizazi 2014 |
|
|
Gel, glass and nematic states of plate-like particle suspensions: charge anisotropy and size effects M. Delhorme; B. Joensson; C. Labbez 2014 |
10.1039/c4ra05555a |
|
Gelation behaviors of denaturated pea albumin and globulin fractions during transglutaminase treatment A. Djoullah; F. Husson; R. Saurel 2018 |
10.1016/j.foodhyd.2017.11.005 |
|
Gem quality and archeological green `jadeite jade' versus `omphacite jade' A. Coccato; S. Karampelas; M. Woerle; S. van Willigen; P. Petrequin 2014 |
10.1002/jrs.4512 |
|
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study J. Edeline; M. Benabdelghani; A. Bertaut; J. Watelet; P. Hammel; J.P. Joly; K. Boudjema; L. Fartoux; K. Bouhier-Leporrier; J.L. Jouve; R. Faroux; V. Guerin-Meyer; J.E. Kurtz; E. Assenat; J.F. Seitz; I. Baumgaertner; D. Tougeron; C. de la Fouchardiere; C. Lombard-Bohas; E. Boucher; T. Stanbury; C. Louvet; D. Malka; J.M. Phelip 2019 |
10.1200/JCO.18.00050 |
|
Gemcitabine induced pulmonary veno-occlusive disease M. Moltenis; C. Turco; M.B. Valnet-Rabier; B. Degano; C. Borg 2015 |
|
|
Gemcitabine induced pulmonary veno-occlusive disease M. Moltenis; C. Turco; M.B. Valnet-Rabier; B. Degano; C. Borg 2015 |
|
|
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study J.M. Phelip; V. Vendrely; F. Rostain; F. Subtil; J.L. Jouve; M. Gasmi; P. Michel; K. Le Malicot; D. Smith; J.F. Seitz; J.P. Fauchart; P. Martin; J. Bennouna; T. Morin; I. Bonnet; P. Maingon; C. Lepage; B. Chauffert 2014 |
10.1016/j.ejca.2014.08.013 |
|
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancerologie Digestive-PRODIGE 37 randomised phase II study (FIR Y. Rinaldi; A.L. Pointet; F.Khemissa Akouz; K. Le Malicot; B. Wahiba; S. Louafi; A. Gratet; L. Miglianico; H. Laharie; K.Bouhier Leporrier; A.Thirot Bidault; P. Texereau; R. Coriat; E. Terrebonne; M.C. Gouttebel; D. Malka; J.B. Bachet; C. Lepage; J. Taieb; P.R.O.D.I.G.E.37 Investi Collabora 2020 |
10.1016/j.ejca.2020.05.018 |
|
Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX). J. Taieb; Y. Rinaldi; A.L. Pointet; E. Barbier; F. Khemissa; A. Gratet; L. Miglianico; H. Laharie-Mineur; K. Bouhier-Leporrier; F. Ghiringhelli; A.Thirot Bidault; P. Texereau; R. Coriat; E. Terrebonne; M.C. Gouttebel; D. Malka; C. Lepage; J.B. Bachet 2018 |
10.1200/JCO.2018.36.15_suppl.4107 |